Clinical Evaluation of Extracellular ADMA Concentrations in Human Blood and Adipose Tissue

• Main Authors: Marcus May, Sandor Batkai, Alexander A. Zörner, Dimitrios Tsikas, Jens Jordan, Stefan Engeli
• Format: Article
• Language: English
• Published: MDPI AG 2014-01-01
• Series: International Journal of Molecular Sciences
• Subjects: asymmetric dimethylarginine; nitric oxide; nitric oxide synthase; dimethylarginine dimethylaminohydrolase; adipose tissue; diabetes; obesity
• Online Access: http://www.mdpi.com/1422-0067/15/1/1189

Circulating asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, has been proposed as a biomarker for clinical outcome. Dimethylarginine dimethylaminohydrolase (DDAH) is the main enzyme responsible for ADMA metabolism and elimination. Adipose tissue ADMA concentrations and DDAH activity and their role in diabetes and obesity have not yet been investigated. In this study, we evaluated clinical microdialysis in combination with a sensitive analytical method (GC-MS/MS) to measure ADMA concentrations in extracellular fluid. Adipose tissue ADMA concentrations were assessed before and during an oral glucose tolerance test in lean healthy subjects and subjects with diabetes (n = 4 each), and in morbidly obese subjects before and after weight loss of 30 kg (n = 7). DDAH activity was determined in subcutaneous and visceral adipose tissue obtained during laparoscopic surgery (n = 5 paired samples). Mean interstitial ADMA concentrations did not differ between study populations (healthy 0.17 ± 0.03 µM; diabetic 0.21 ± 0.03 µM; morbidly obese 0.16 ± 0.01 and 0.17 ± 0.01 µM before and after weight loss, respectively). We did not observe any response of interstitial ADMA concentrations to the oral glucose challenge. Adipose tissue DDAH activity was negligible compared to liver tissue. Thus, adipose tissue ADMA plays a minor role in NO-dependent regulation of adipose tissue blood flow and metabolism.